ZURA (Zura Bio) Ending Cash Position: $205.13 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ZURA Zura Bio Ltd ZURA
22 GF Score
Price $5.58
! 1 Warning Sign
View Full Analysis

What is Zura Bio Ending Cash Position?

Zura Bio ZURA -1.07% 22 Ending Cash Position is $205.13 Mil as of Jun. 2026. GuruFocus rates ZURA with a GF Score™ of 22/100. The stock has 1 warning sign investors should review.

Zura Bio's Ending Cash Position for the quarter that ended in Jun. 2026 was $205.13 Mil.

Zura Bio's quarterly Ending Cash Position increased from Dec. 2025 ($109.41 Mil) to Mar. 2026 ($225.59 Mil) but then declined from Mar. 2026 ($225.59 Mil) to Jun. 2026 ($205.13 Mil).

Zura Bio's annual Ending Cash Position increased from Dec. 2023 ($99.81 Mil) to Dec. 2024 ($176.50 Mil) but then declined from Dec. 2024 ($176.50 Mil) to Dec. 2025 ($109.41 Mil).

Zura Bio Ending Cash Position Related Terms

Zura Bio Ending Cash Position Historical Data

* Premium members only.

The historical data trend for Zura Bio's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Zura Bio Ending Cash Position Chart

Zura Bio Annual Data
Trend Mar22 Dec23 Dec24 Dec25
Ending Cash Position
0.00 99.81 176.50 109.41

Zura Bio Quarterly Data
Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Ending Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 154.49 139.02 109.41 225.59 205.13
ZURA
22GF Score
Zura Bio Ltd ZURA
Ending Cash Position is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Zura Bio Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

Zura Bio's Ending Cash Position for the fiscal year that ended in Dec. 2025 is calculated as

Ending Cash Position= Beginning Cash Position+Net Change in Cash
=176.498+-67.091
=109.41

Zura Bio's Ending Cash Position for the quarter that ended in Jun. 2026 is calculated as

Ending Cash Position=Beginning Cash Position+Net Change in Cash
=225.594+-20.46
=205.13

Frequently Asked Questions Learn more about Ending Cash Position →
What does a Ending Cash Position of $205.13 Mil mean?
Zura Bio (ZURA) has a Ending Cash Position of $205.13 Mil as of Jun. 2026. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on Zura Bio and its competitors.
Is Zura Bio's Ending Cash Position too high?
Zura Bio's current Ending Cash Position is $205.13 Mil. Overall, Zura Bio has a GF Score™ of 22/100, reflecting its overall financial health beyond just this single metric.
How does Zura Bio's Ending Cash Position compare to ASMB and ARTV?
Zura Bio's Ending Cash Position of $205.13 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Ending Cash Position for a Biotechnology company?
A good Ending Cash Position depends on the Biotechnology industry context. However, Ending Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Ending Cash Position mean?
A high Ending Cash Position can signal that a stock is expensive relative to its fundamentals. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on Zura Bio and its competitors. Zura Bio's current Ending Cash Position is $205.13 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Zura Bio stock overvalued right now?
Zura Bio (ZURA) has a current Ending Cash Position of $205.13 Mil. The current Ending Cash Position is $205.13 Mil. Zura Bio's overall GF Score™ is 22/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Ending Cash Position calculated?
Ending Cash Position is calculated from a company's financial statements. For Zura Bio (ZURA), the current Ending Cash Position is $205.13 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Zura Bio Business Description

Other Exchanges 94E:Germany
Address 1489 W. Warm Springs Road, Suite 110, Henderson, NV, USA, 89014
Zura Bio Ltd is a clinical-stage biotechnology company developing novel medicines for patients with autoimmune and inflammatory diseases, including serious and debilitating conditions with unmet medical need. These diseases are often chronic, biologically complex, and difficult to treat, and many patients do not achieve durable disease control with existing therapies. The company has in-licensed three clinical-stage product candidates: Tibulizumab (ZB-106), a bispecific antibody targeting IL-17A and BAFF; Crebankitug (ZB-168), an IgG1 monoclonal antibody targeting IL-7R; and Torudokimab (ZB-880), an IgG4 monoclonal antibody targeting IL-33.
22GF Score

Get the complete analysis for ZURA

Ending Cash Position is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$5.58
Price